相似文献
1
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.
Clin Pharmacol Ther. 2010 Apr;87(4):473-8. doi: 10.1038/clpt.2010.2. Epub 2010 Mar 3.
2
Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?
Annu Rev Pharmacol Toxicol. 2016;56:605-626. doi: 10.1146/annurev-pharmtox-010715-103209.
3
Novel therapeutic targets for cholestatic and fatty liver disease.
Gut. 2022 Jan;71(1):194-209. doi: 10.1136/gutjnl-2021-324305. Epub 2021 Oct 6.
4
Nuclear receptors in acute and chronic cholestasis.
Dig Dis. 2015;33(3):357-66. doi: 10.1159/000371688. Epub 2015 May 27.
5
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
Semin Liver Dis. 2016 Feb;36(1):69-86. doi: 10.1055/s-0036-1571296. Epub 2016 Feb 12.
6
Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.
Chem Biol Interact. 2010 Mar 30;184(3):376-87. doi: 10.1016/j.cbi.2010.01.008. Epub 2010 Jan 15.
7
Nuclear receptors in liver disease.
Hepatology. 2011 Mar;53(3):1023-34. doi: 10.1002/hep.24148. Epub 2011 Feb 11.
8
Farnesoid X receptor modulators (2011 - 2014): a patent review.
Expert Opin Ther Pat. 2015;25(8):885-96. doi: 10.1517/13543776.2015.1045413.
9
Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.
Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2599-630. doi: 10.2741/3400.
10
Look who's talking: nuclear receptors in the liver and gastrointestinal tract.
Cell Metab. 2008 Mar;7(3):195-9. doi: 10.1016/j.cmet.2008.02.006.
引用本文的文献
1
Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.
Med Pharm Rep. 2024 Apr;97(2):111-119. doi: 10.15386/mpr-2628. Epub 2024 Apr 25.
2
Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.
Front Pharmacol. 2023 Mar 16;14:1081334. doi: 10.3389/fphar.2023.1081334. eCollection 2023.
3
Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.
Chin Med. 2021 Jul 27;16(1):62. doi: 10.1186/s13020-021-00470-x.
4
Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p.
Mol Ther Nucleic Acids. 2019 Dec 6;18:954-965. doi: 10.1016/j.omtn.2019.10.018. Epub 2019 Oct 25.
5
Exposure to 2,4-dichlorophenoxyacetic acid induced PPARβ-dependent disruption of glucose metabolism in HepG2 cells.
Environ Sci Pollut Res Int. 2018 Jun;25(17):17050-17057. doi: 10.1007/s11356-018-1921-6. Epub 2018 Apr 9.
6
Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet.
PLoS One. 2018 Feb 13;13(2):e0192863. doi: 10.1371/journal.pone.0192863. eCollection 2018.
7
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.
Front Pharmacol. 2016 Sep 28;7:345. doi: 10.3389/fphar.2016.00345. eCollection 2016.
8
RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.
Biochim Biophys Acta. 2016 Sep;1859(9):1198-1217. doi: 10.1016/j.bbagrm.2016.04.010. Epub 2016 Apr 23.
9
Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?
Annu Rev Pharmacol Toxicol. 2016;56:605-626. doi: 10.1146/annurev-pharmtox-010715-103209.
10
Biological functions of thyroid hormone in placenta.
Int J Mol Sci. 2015 Feb 16;16(2):4161-79. doi: 10.3390/ijms16024161.
本文引用的文献
1
Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.
J Biol Chem. 2010 Jan 29;285(5):3428-38. doi: 10.1074/jbc.M109.074252. Epub 2009 Nov 24.
2
Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease.
Curr Drug Targets. 2009 Nov;10(11):1156-1163. doi: 10.2174/138945009789735174.
3
Fatty liver and lipotoxicity.
Biochim Biophys Acta. 2010 Mar;1801(3):299-310. doi: 10.1016/j.bbalip.2009.10.007. Epub 2009 Oct 24.
4
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease.
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18831-6. doi: 10.1073/pnas.0909731106. Epub 2009 Oct 22.
5
Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications.
Aliment Pharmacol Ther. 2009 Oct 15;30(8):816-25. doi: 10.1111/j.1365-2036.2009.04104.x. Epub 2008 Jul 23.
6
New molecular insights into the mechanisms of cholestasis.
J Hepatol. 2009 Sep;51(3):565-80. doi: 10.1016/j.jhep.2009.05.012. Epub 2009 May 28.
7
Adipokines in liver diseases.
Hepatology. 2009 Sep;50(3):957-69. doi: 10.1002/hep.23046.
8
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
Ann Med. 2009;41(4):265-78. doi: 10.1080/07853890802552437.
9
Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.
Front Biosci (Landmark Ed). 2009 Jan 1;14(7):2599-630. doi: 10.2741/3400.
10
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Diabetes Metab. 2008 Dec;34(6 Pt 2):685-91. doi: 10.1016/S1262-3636(08)74605-6.
Zotero 插件